Catalyst Pharmaceuticals (CPRX) Non Operating Income (2014 - 2026)

Catalyst Pharmaceuticals has reported Non Operating Income for 13 years, with the latest figure at $11.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 38.87% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $28.8 million (up 6.35% YoY), and the FY2025 full-year result was $25.7 million, up 21.75% from the prior year.
• Non Operating Income for Q1 2026 stood at $11.0 million, up from $10.1 million in the prior quarter.
• The five-year high for Non Operating Income was $11.3 million in Q4 2024, with the low at -$833000.0 in Q3 2023.
• Historically, Non Operating Income has averaged $4.0 million across 5 years, with a median of $2.2 million in 2022.
• The largest YoY upside for Non Operating Income was 3008.45% in 2022 against a maximum downside of 622.58% in 2022.
• Catalyst Pharmaceuticals' Non Operating Income stood at $2.2 million in 2022, then jumped by 127.23% to $5.0 million in 2023, then jumped by 126.08% to $11.3 million in 2024, then retreated by 11.32% to $10.1 million in 2025, then advanced by 9.37% to $11.0 million in 2026.
• The last three Non Operating Income figures came in at $11.0 million (Q1 2026), $10.1 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.